Format

Send to

Choose Destination
Eur Respir J. 2018 May 17;51(5). pii: 1702678. doi: 10.1183/13993003.02678-2017. Print 2018 May.

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Author information

1
World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Care and Research Institute, Tradate, Italy.
2
Contributed equally.
3
Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari, Sassari, Italy.
4
European Centre for Disease Prevention and Control, Stockholm, Sweden.
5
Public Health Consulting Group, Lugano, Switzerland.
6
Institute for Global Health, University College London, London, UK.
7
Homerton University Hospital, London, UK.
8
Pneumology Dept, Hospital General de Gran Canaria "Dr. Negrin", Las Palmas de Gran Canaria, Spain.
9
MDR-TB Unit, Tuberculosis Division, International Union against Tuberculosis and Lung Disease (The Union), Paris, France.
10
Emerging Bacterial Pathogens Unit, Div. of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milano, Italy.
11
World Health Organization, Regional Office for Europe, UN City, Copenhagen, Denmark.
12
KNCV Tuberculosis Foundation, Den Haag, The Netherlands.
13
School of Medicine and Surgery, University of Milan-Bicocca, UO Clinica Pneumologica, AO San Gerardo, Monza, Italy.
14
Dept of Respiratory Physiology, Cochin Hospital, Paris Descartes University, Paris, France.
15
National Reference Centre for MDR-TB, Hospital Centre Vila Nova de Gaia, Dept of Pneumology; Public Health Science and Medical Education Department, Faculty of Medicine, University of Porto, Porto, Portugal.
16
Dept of Paediatrics, Paediatric Emergency Unit, "Sapienza" University of Rome, Rome, Italy.
17
National Institute for TB, Lung Diseases and Thoracic Surgery, Vysne Hagy, Catholic University Ruzomberok, Ruzomberok, Slovakia.
18
Clinic of Thoracic Surgery, Belgrade, Serbia.
19
Dept of Biomedicine and Prevention and Animal Technology Station, University of Rome "Tor Vergata", Rome, Italy.
20
Regional Health Administration of the North, Dept of Public Health, Porto, Portugal.
21
Centre of TB and Lung Diseases, Riga East University Hospital, Riga, Latvia.
22
Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases "L. Spallanzani", IRCCS, Rome, Italy.
23
Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London UK.
24
Dept of Methodology and Supervision, Riga East University Hospital, Riga, Latvia.
25
Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
26
Verduin Public Health Consult, Oegstgeest, The Netherlands.

Abstract

The International Standards for Tuberculosis Care define the essential level of care for managing patients who have or are presumed to have tuberculosis, or are at increased risk of developing the disease. The resources and capacity in the European Union (EU) and the European Economic Area permit higher standards of care to secure quality and timely TB diagnosis, prevention and treatment. On this basis, the European Union Standards for Tuberculosis Care (ESTC) were published in 2012 as standards specifically tailored to the EU setting. Since the publication of the ESTC, new scientific evidence has become available and, therefore, the standards were reviewed and updated.A panel of international experts, led by a writing group from the European Respiratory Society (ERS) and the European Centre for Disease Prevention and Control (ECDC), updated the ESTC on the basis of new published evidence. The underlying principles of these patient-centred standards remain unchanged. The second edition of the ESTC includes 21 standards in the areas of diagnosis, treatment, HIV and comorbidities, and public health and prevention.The ESTC target clinicians and public health workers, provide an easy-to-use resource and act as a guide through all the required activities to ensure optimal diagnosis, treatment and prevention of TB.

PMID:
29678945
DOI:
10.1183/13993003.02678-2017
[Indexed for MEDLINE]

Conflict of interest statement

Conflict of interest: S. Aliberti reports grants and personal fees from Bayer Healthcare, Aradigm Corporation, Grifols, Chiesi and INSMED, and personal fees from AstraZeneca, Basilea, Zambon, Novartis, Raptor, Actavis UK Ltd and Horizon, outside the submitted work.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center